Cardiac amyloidosis was once considered untreatable. Now, we have effective treatments, less invasive diagnostic tests, and a growing body of research in this complex disease.
For decades, there were no FDA-approved treatments for cardiac amyloidosis in the U.S. But in the last two years, two new therapies were approved for cardiac- and nerve-related ATTR. In this week's MedBlog, Justin Grodin, M.D., discusses these therapies and what they mean for North Texas patients.
